Yahoo
    NasdaqGS - Nasdaq Real Time Price USD

    Vor Biopharma Inc. (VOR)

    19.68 -1.23 (-5.88%)
    At close: October 30 at 4:00:00 PM EDT
    19.75 +0.07 (+0.36%)
    After hours: October 30 at 5:12:44 PM EDT
    Trade VOR on Coinbase
    Chart Range Bar
    Advanced Chart
    AlphaSpace Chart
    Loading chart for VOR
    • Previous Close 20.91
    • Open 19.91
    • Bid 14.53 x 200
    • Ask 24.87 x 200
    • Day's Range 19.37 - 20.47
    • 52 Week Range 6.50 - 26.00
    • Volume 759,595
    • Avg. Volume 950,314
    • Market Cap (intraday) 1.209B
    • Beta (5Y Monthly) 1.78
    • PE Ratio (TTM) 0.07
    • EPS (TTM) 300.56
    • Earnings Date Oct 30, 2026
    • Forward Dividend & Yield -- (0.00%)
    • 1y Target Est 39.00
    • Zacks Rating Neutral

    Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

    www.vorbio.com

    76

    Full Time Employees

    December 31

    Fiscal Year Ends

    Healthcare

    Sector

    Biotechnology

    Industry

    More about Vor Biopharma Inc.

    Recent News

    View More
    View More

    Performance Overview

    Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

    YTD Return

    VOR
    50.46%
    S&P 500 (^GSPC)
    10.73%

    1-Year Return

    VOR
    21.28%
    S&P 500 (^GSPC)
    11.11%

    3-Year Return

    VOR
    52.69%
    S&P 500 (^GSPC)
    81.91%

    5-Year Return

    VOR
    93.74%
    S&P 500 (^GSPC)
    64.59%

    Earnings Trends

    View More

    Earnings Per Share

    GAAP
    Normalized
    GAAP
    Normalized

    Revenue vs. Earnings

    Annual
    Quarterly
    Annual
    Quarterly
    Q3 FY26
    Revenue --
    Earnings -86.73M
    Profit Margin 0.00%

    Q4

    FY25

    Q1

    FY26

    Q2

    FY26

    Q3

    FY26

    0
    500M
    1B
    2B
    0.0%
    View More

    Analyst Insights

    View More

    Analyst Price Targets

    27.00
    39.00 Average
    19.68 Current
    50.00 High

    Analyst Recommendations

    • Strong Buy
    • Buy
    • Hold
    • Underperform
    • Sell

    Latest Rating

    Date 10/21/2026
    Analyst William Blair
    Rating Action Initiated
    Rating Outperform
    Price Action --
    Price Target --
    View More

    Statistics

    View More

    Valuation Measures

    Annual

    • Market Cap

    • Enterprise Value

    • Trailing P/E

    • Forward P/E

    • PEG Ratio (current)

    • Price/Sales (ttm)

    • Price/Book (mrq)

    • Enterprise Value/Revenue

    • Enterprise Value/EBITDA

    Financial Highlights

    Profitability and Income Statement

    • Profit Margin

      0.00%

    • Return on Assets (ttm)

      -27.45%

    • Return on Equity (ttm)

      --

    • Revenue (ttm)

      --

    • Net Income Avi to Common (ttm)

      1.35B

    • Diluted EPS (ttm)

      300.56

    Balance Sheet and Cash Flow

    • Total Cash (mrq)

      481.55M

    • Total Debt/Equity (mrq)

      --

    • Levered Free Cash Flow (ttm)

      -46.94M

    View More

    Company Insights

    Research Reports

    View More
    View More

    People Also Watch

    IMCR
    CGEM
    DSGN
    BCAB
    SANA
    Mobilize your Website
    View Site in Mobile | Classic
    Share by: